Media

GenSight Biologics Reports its Cash Position as of September 30, 2019 and Provides Operational Update

Nordic Nanovector – Private placement successfully completed

Strongbridge Biopharma plc Presents KEVEYIS® (dichlorphenamide) Primary Periodic Paralysis (PPP) Data at the 2019 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting

Nordic Nanovector Presentations at the Annual Congress of the European Association of Nuclear Medicine (EANM)

GenSight Biologics reports evidence of GS010 DNA transfer to contralateral eye of primates unilaterally injected with GS010 Gene Therapy

Camel-IDS appoints Ruggero Della Bitta MD, PhD, as Chief Medical Officer

GenSight Biologics Appoints Magali Taiel as Chief Medical Officer

GenSight Biologics to present new GS010 data at the 2019 Annual Meeting of the American Academy of Ophthalmology

Aprea Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares